NCT02364999 is a Phase 3 clinical trial of Bevacizumab-Pfizer in Non-Small Cell Lung Cancer, sponsored by Pfizer.

Who is sponsoring NCT02364999?

NCT02364999 is sponsored by Pfizer.

What drugs are being tested in NCT02364999?

Interventions in NCT02364999: Bevacizumab-Pfizer, Bevacizumab-EU, Paclitaxel, Carboplatin.

What condition does NCT02364999 study?

NCT02364999 studies Non-Small Cell Lung Cancer.

Is NCT02364999 still recruiting?

NCT02364999 is currently completed. Last updated 18 January 2019.

Are results published for NCT02364999?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-01-18 · How we verify

NCT02364999

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER.

Completed Phase 3 Results posted Last updated 18 January 2019

What this trial tests

Phase 3 trial testing Bevacizumab-Pfizer in Non-Small Cell Lung Cancer in 719 participants. Completed in 1 December 2017.

Timeline

1 April 2015

Primary endpoint
1 May 2017

1 December 2017

Quick facts

Lead sponsor	Pfizer
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	719
Start date	1 April 2015
Primary completion	1 May 2017
Estimated completion	1 December 2017
Sites	263 locations across United States, Australia, Brazil, Bulgaria, Chile, Croatia, Czechia, France

Drugs / interventions tested

Bevacizumab-Pfizer — full drug profile →
Bevacizumab-EU (bevacizumab-eu) — full drug profile →
Paclitaxel — full drug profile →
Carboplatin (Carboplatin) — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Objective Response Rate (ORR) by Week 19
Time frame: 25 weeks
ORR refers to percentage of participants who achieved complete response (CR) or partial response (PR) by Week 19 of the study in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 which was subsequently confirmed by Week 25. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-targ

Sponsor's own description

This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.
Rosen LS, Jacobs IA, Burkes RL. · · 2017 · cited 114× · PMID 28801849 · DOI 10.1007/s11523-017-0518-1
State of the art in anti-cancer mAbs.
Chiavenna SM, Jaworski JP, Vendrell A. · · 2017 · cited 52× · PMID 28219375 · DOI 10.1186/s12929-016-0311-y
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin<sup>®</sup>), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study.
Reinmuth N, Bryl M, Bondarenko I, Syrigos K, et al · · 2019 · cited 40× · PMID 31338773 · DOI 10.1007/s40259-019-00363-4
A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Knight B, Rassam D, Liao S, Ewesuedo R. · · 2016 · cited 33× · PMID 26984210 · DOI 10.1007/s00280-016-3001-2
Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives.
Yang J, Liu R, Ektare V, Stephens J, et al · · 2021 · cited 17× · PMID 33506318 · DOI 10.1007/s40258-021-00637-5
Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.
Chan SHY, Khatib Y, Webley S, Layton D, et al · · 2023 · cited 10× · PMID 37383708 · DOI 10.3389/fphar.2023.1137983
Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin<sup>®</sup>) in patients with advanced non-squamous non-small cell lung cancer.
Li CSW, Sweeney K, Cronenberger C. · · 2020 · cited 10× · PMID 31768697 · DOI 10.1007/s00280-019-03946-8
Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis.
Xu X, Zhang S, Xu T, Zhan M, et al · · 2022 · cited 8× · PMID 35865968 · DOI 10.3389/fphar.2022.880090

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02364999 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 18 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02364999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing